Inmune Bio, Inc. (INMB) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Inmune Bio reported revenue of $50,000, up 257.1% from $14,000 the year before. Net income was -$45.9M (a -91866.0% net margin), or -$1.86 per diluted share. Operating margin was -94766.0%. Operating activities generated -$22.6M of cash, leaving -$23.6M of free cash flow. At fiscal year end, Inmune Bio held $32.4M in total assets against $8.8M in total liabilities, including $24.8M of cash and equivalents.
Open the full interactive Inmune Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Inmune Bio Key Stats
| Share Price | $1.68 |
|---|---|
| Market Cap | $44.9M |
| Revenue YoY Growth | +257.1% |
| 52-Week Range | $1.12 – $2.51 |
| Shares Outstanding | 26.7 million (basic, 2026 Q2) |
Inmune Bio Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10,916 | $181,000 | $374,000 | $155,000 | $14,000 | $50,000 |
| Operating Income | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$47.4M |
| Pre-Tax Income | -$12.1M | -$30.3M | -$27.3M | -$30.0M | $42.1M | $45.9M |
| Income Tax | — | — | — | — | $84.2M | $91.9M |
| Net Income | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Diluted EPS | -$1.01 | -$1.88 | -$1.52 | -$1.67 | -$2.11 | -$1.86 |
Inmune Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$6.5M | -$5.3M | -$5.4M | -$1.3M |
| Diluted EPS | -$0.24 | -$0.21 | -$0.20 | -$0.05 |
Inmune Bio Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Current Assets | $24.0M | $82.6M | $64.7M | $39.9M | $22.7M | $29.9M |
| Total Assets | $40.7M | $99.9M | $81.8M | $57.0M | $39.6M | $32.4M |
| Current Liabilities | $1.8M | $4.4M | $10.9M | $18.5M | $7.2M | $8.4M |
| Total Long-Term Debt | — | $15.0M | $15.0M | $14.9M | — | — |
| Total Liabilities | $1.9M | $19.7M | $21.7M | $18.9M | $7.5M | $8.8M |
| Shareholders' Equity | $38.8M | $80.2M | $60.1M | $37.3M | $32.1M | $23.5M |
Inmune Bio Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Cash From Investing | $19,223 | -$15.0M | — | — | — | -$1.0M |
| Cash From Financing | $23.9M | $96.4M | $729,000 | -$4.2M | $18.2M | $27.6M |
| Free Cash Flow | — | — | — | — | -$33.4M | -$23.6M |
Figures from Inmune Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Inmune Bio financials page for every line item.
Inmune Bio Company Profile
| Ticker | INMB |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boca Raton, Florida |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001711754 |
Frequently Asked Questions
What was Inmune Bio's revenue in fiscal 2025?
Inmune Bio (INMB) reported revenue of $50,000 for fiscal 2025.
What is Inmune Bio's annual revenue history?
Inmune Bio's annual revenue by fiscal year: 2020: $10,916; 2021: $181,000; 2022: $374,000; 2023: $155,000; 2024: $14,000; 2025: $50,000.
What was Inmune Bio's net income in fiscal 2025?
Inmune Bio reported net income of -$45.9M for fiscal 2025.
What was Inmune Bio's earnings per share (EPS) in fiscal 2025?
Inmune Bio's diluted EPS was -$1.86 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Inmune Bio generate in fiscal 2025?
Inmune Bio generated -$23.6M of free cash flow in fiscal 2025.
How many shares of Inmune Bio are outstanding?
Inmune Bio reported a weighted average of 26.7 million basic shares outstanding in 2026 Q2.
What is Inmune Bio's market cap?
Based on its latest closing price, Inmune Bio (INMB) has a market capitalization of about $44.9M.
When does Inmune Bio's fiscal year end?
Inmune Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Inmune Bio headquartered?
Inmune Bio lists its business address in Boca Raton, Florida in its SEC filings.